Computer simulations suggest that propylthiouracil begins to significantly stress liver cells through oxidative damage at doses of 200 mg per day or higher, indicating that lower doses may carry less risk.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether clinical data consistently show increased ALT elevation rates above 200 mg/day of PTU compared to lower doses across diverse populations.
A systematic review and meta-analysis of all published prospective studies and clinical trials reporting ALT >2×ULN incidence in patients receiving PTU at doses <200 mg/day, 200–300 mg/day, and >300 mg/day, with adjustment for treatment duration, age, and comorbidities, including at least 8,000 patient-years of exposure.
An RCT could test whether patients randomized to 150 mg/day vs. 250 mg/day of PTU differ in the incidence of ALT elevation over time, directly validating the predicted threshold.
A double-blind RCT of 300 adults with hyperthyroidism randomized to PTU at 150 mg/day, 200 mg/day, or 250 mg/day for 16 weeks, with weekly ALT measurements as the primary outcome, excluding those with pre-existing liver disease or concomitant hepatotoxins.
A cohort study could track the incidence of ALT elevation in patients prescribed PTU at different daily doses over time to determine if 200 mg/day is a consistent inflection point.
A prospective cohort study following 7,000 patients prescribed PTU for hyperthyroidism, stratified by daily dose (<150 mg, 150–200 mg, 201–300 mg), with monthly ALT monitoring for 2 years, adjusting for BMI, age, and genetic risk variants.
A case-control study could determine whether patients who developed ALT >2×ULN were more likely to have been on PTU doses ≥200 mg/day than those who did not.
A case-control study comparing 400 patients with PTU-induced ALT >2×ULN to 1,200 matched controls without liver injury, assessing prior PTU dose (categorized as <200 mg/day vs. ≥200 mg/day), duration of use, and genetic markers, using pharmacy and electronic health records.
A cross-sectional analysis could describe the proportion of patients with elevated ALT among those currently taking PTU at different dose levels.
A cross-sectional survey of 4,000 adults currently taking PTU for hyperthyroidism, measuring current dose and ALT level at a single visit, with exclusion of acute illness or other liver disease causes.